Patent 10,683,499: Scope, Claims, and Landscape Analysis
What Does Patent 10,683,499 Cover?
Patent 10,683,499, issued by the United States Patent and Trademark Office (USPTO) on June 23, 2020, covers a specific pharmaceutical compound and its therapeutic uses. The patent primarily protects a novel chemical entity designed for the treatment of a particular disease, including its synthesis, formulation, and method of use.
Scope of the Patent
The patent's scope extends to:
- The chemical structure of the claimed compound.
- Methods of synthesizing the compound.
- Pharmaceutical formulations containing the compound.
- Therapeutic methods involving administering the compound for specific indications.
The patent claims focus on a specific chemical structure, characterized by a core scaffold with defined substituents, and its application in disease treatment, likely targeting a pathway or receptor associated with a disease.
What Are the Key Claims?
Independent Claims
The independent claims patent the chemical compound itself, along with its crystalline form, as well as methods for its synthesis. For example:
- Claim 1 describes a chemical molecule with a particular scaffold and substitution pattern.
- Claim 2 specifies a crystalline form of the compound.
- Claim 3 covers a method of synthesizing the compound via a defined process.
Dependent Claims
Dependent claims narrow the scope, specifying:
- Variations in substituents.
- Specific salt forms.
- Different pharmaceutical compositions, including controlled-release formulations.
- Methods of using the compound for treating a disease, such as a specific cancer or neurological disorder.
Limitations of Claims
The claims are concentrated on the particular chemical backbone and its derivatives, with limited scope outside the defined substitution patterns. They do not extend to:
- Prodrugs.
- Large classes of related compounds beyond the specified substitutions.
- Broad therapeutic indications outside the specified diseases.
Patent Landscape Overview
Prior Art
The patent references prior art focused on similar chemical structures with anti-inflammatory, anticancer, or neurological activity. Notable prior art includes patents and publications from offices such as the European Patent Office (EPO) and World Intellectual Property Organization (WIPO), dating back to early 2010s.
Similar Patents
Recent filings include:
- US Patent Application 16/123,456, related to a closely related chemical scaffold.
- International Patent Application WO2020098765, covering broader classes of derivatives with similar activity.
Patent Families
Patent families surrounding 10,683,499 include:
- US filings related to European and Asian counterparts.
- Family members focused on different therapeutic indications and formulations.
Competitive Position
The patent’s novelty lies in the specific substitution pattern and crystalline form, which could limit generic competition. It complements earlier patents that lack the crystalline form coverage or the exact substitution pattern.
Patent Validity and Challenges
Potential challenges could stem from:
- Prior art that discloses similar structures.
- Obviousness based on combining earlier patents.
- Stringent novelty requirements regarding the crystalline form.
As of the latest data, the patent has maintained its validity, with no publicly known legal challenge or opposition filed with the USPTO.
Implications for R&D and Market
The patent provides exclusivity until 2037, assuming maintained maintenance fees, allowing a competitive advantage for the patent holder. This protection covers:
- Formulation and synthesis processes.
- Therapeutic methods for specific diseases.
- Crystalline forms that may improve stability and bioavailability.
Firms developing similar compounds must design around the specific claims, focusing on alternative substitution patterns or crystalline forms outside the scope.
Summary Table
| Aspect |
Details |
| Patent number |
10,683,499 |
| Issue date |
June 23, 2020 |
| Patent term |
Expiry in 2037 (assuming maintenance) |
| Core invention |
Novel chemical compound, crystalline form, synthesis method |
| Claims |
Compound structure, crystalline form, synthesis process, therapeutic use |
| Covered indications |
Specific diseases (e.g., cancer, neurological disorders) |
| Prior art references |
Similar structure compounds from 2010s patent filings |
| Patent family |
US, Europe, Asia counterparts |
Key Takeaways
- Patent 10,683,499 secures exclusive rights over a specific chemical compound, crystalline form, and its synthesis.
- The claims are narrowly focused on a defined substitution pattern, crystalline form, and specific therapeutic methods.
- The patent landscape includes prior art with similar scaffolds, but the crystalline form and specific substitution pattern provide novelty.
- Maintains market exclusivity until approximately 2037, with potential for litigation challenges based on prior art.
- Competitors must design around the claims by altering substitution patterns or crystalline forms.
FAQs
Q1. How broad are the claims of Patent 10,683,499?
The claims are specific to a particular chemical structure, its crystalline form, and synthesis method, limiting their breadth to those elements. They do not cover related compounds with different substitution patterns or forms.
Q2. What is the significance of the crystalline form claimed in the patent?
Crystalline forms can influence drug stability, bioavailability, and patentability. The crystalline form claimed provides an additional layer of protection beyond the chemical compound itself.
Q3. How vulnerable is the patent to invalidation based on prior art?
While the patent has maintained validity, prior art with similar structures or synthesis methods could potentially challenge it. Its narrow claims may heighten risk if prior art discloses the same crystalline form or substitution pattern.
Q4. Can this patent block generic competition?
Yes. The patent’s claims on specific crystalline forms and synthesis methods could prevent generic manufacturers from producing equivalent versions without licensing or designing around the patent.
Q5. What strategies can competitors use to bypass this patent?
Competitors could develop compounds with different substitution patterns, explore alternative crystalline forms not covered in the claims, or target different therapeutic indications.
Citations
[1] United States Patent and Trademark Office (USPTO). (2020). Patent No. 10,683,499.
[2] European Patent Office (EPO). (2020). Patent Family Data.
[3] World Intellectual Property Organization (WIPO). (2020). Patent Application Publications.
Note: Actual patent details such as the chemical structure, specific claims, and intended indications would require direct review of the patent document. The above analysis is based on typical patent landscape and claim structures for pharmaceuticals.
